Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.
Videos
Thomas Powles, MD, MBBS, MRCP, discusses the safety profile of enfortumab vedotin in urothelial cancers as observed in the phase 3 urothelial cancerstrial.
Next steps investigating novel-based therapies for newly diagnosed metastatic renal cell carcinoma.
Advice to oncology nurses who manage patients with metastatic renal cell carcinoma receiving novel-based therapies, including lenvatinib and pembrolizumab.
An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.
Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab, based on the regimen’s performance in the CLEAR study compared with other options.
Reactions to efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab as first-line treatment for metastatic renal cell carcinoma.
The rationale for investigating the combinations of lenvatinib plus pembrolizumab and lenvatinib plus everolimus as frontline therapy for metastatic renal cell carcinoma.
An overview of current novel-based approaches for metastatic renal cell carcinoma and current treatment gaps.
Dana Chase, MD, discusses frontline therapy options for patients with advanced ovarian cancer.
Karen Reckamp, MD, and Jyoti Patel, MD, review currently available frontline treatment options for ALK+ advanced NSCLC and discuss updated efficacy and safety data from key clinical trials of these agents in advanced NSCLC.
Jyoti Patel, MD, elucidates the mechanism of action of various ALK targeting agents in NSCLC and the optimal formulations and dosing strategies in patients with advanced NSCLC.
Treatment advice for community oncologists and hematologists who treat follicular lymphoma based on therapeutic advances occurring rapidly in the field.
Treatment options and variables that need to be considered when managing patients with follicular lymphoma who relapse early after first-line chemoimmunotherapy.
Factors that affect the use of maintenance therapy, including anti-CD20 maintenance therapy, for newly diagnosed follicular lymphoma, and recommendations for assessing response to therapy.
The rationale for treating newly diagnosed follicular lymphoma with the anti-CD20 monoclonal antibody, obinutuzumab, in the first-line setting.
Goals of therapy and variables that affect how patients with newly diagnosed follicular lymphoma are managed with chemoimmunotherapy in the frontline setting, including during COVID-19.
Recommendations for assessing and risk stratifying patients with newly diagnosed follicular lymphoma, with special considerations regarding the current role of molecular testing.
Similarities between the management of a hypothetical case of newly diagnosed follicular lymphoma compared with what is done in real-world practice.
Marshall Posner, MD, discusses a study exploring the use of HB-201 and HB-202 vaccines in patients with HPV16-positive cancers.
Erika Hamilton, MD, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.
Richard Anderson, MD, PhD, discusses ways to preserve fertility in patients who are undergoing or have complete treatment for lymphoma.
Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.
Dana Chase, MD of Arizona Oncology, discusses frontline treatment of ovarian cancer and the challenges faced in the community oncology setting.
Carole Miller, MD, discusses the REVEAL trial design, an observational study on mortality and causes of death in patients with polycythemia vera.
In the fourth video of the series, Jorge Garcia, MD, FACP, considers PSMA-positive cells as a therapeutic target in men with metastatic castration-resistant prostate cancer and discusses the implications of the VISION trial for the therapeutic landscape.
Alexander Spira, MD, PhD, FACP, discusses the prognosis of patients with EGFR- exon 20 mutated non-small cell lung cancer.
Expert perspectives on the case of a 70-year-old man who presents and is diagnosed with solitary hepatocellular carcinoma measuring greater than 3cm.
Clinical pearls regarding molecular testing and treatment selection in metastatic cholangiocarcinoma.
Implications for treating select patients with metastatic cholangiocarcinoma with ivosidenib as second-line therapy.